Research Nester released a report titled “Ebola Vaccine Market: Global Demand Analysis & Opportunity Outlook 2027” which delivers detailed overview of the global Ebola vaccine market in terms of market segmentation by virus type, by end user and by region.
Further, for the in-depth analysis, the report encompasses the industry growth drivers, restraints, supply and demand risk, market attractiveness, BPS analysis and Porter’s five force model.
The Ministry of Health in Democratic Republic of the Congo reported that as of March 10, 2020, there have been a total of 3,444 cases, out of which 3,310 are confirmed and 134 are probable. This number includes 2,264 deaths, 1,169 survivors as well as the patients that are still under care. This has been labelled as the world’s second largest Ebola epidemic and was declared on August 1, 2018.
Ebola is a deadly viral disease that is transmitted from infected animals or infected humans. It causes high fever, diarrhea, body aches and bleeding. Eventually, the disease damages the body organs and the immune system, which turns out to be fatal in a majority of cases. The market for Ebola vaccine is projected to grow at a significantly high CAGR over the forecast period, i.e., 2020-2028. The market is segmented by virus type, by end user and by region. Out of these, the virus type segment is further segmented into Ebola virus, Sudan virus, Taï Forest virus and Bundibugyo virus. The Ebola virus segment is predicted to grow at the highest rate over the forecast period on account of growing prevalence of Ebola virus disease caused by this strain of virus.
Geographically, the Ebola vaccine market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa, out of which, the market in North America is anticipated to hold the leading share and grow at the highest rate during the next few years. This can be attributed to the growing research and development activities by various leading pharmaceutical companies in the region, mainly in the United States.
Increasing Occurrence of Ebola Virus Disease to Impact the Market Growth Positively
The rising number of deaths due to the Ebola virus disease is increasing the demand for drugs and vaccines that are either preventive or provide effective treatment methods for the disease. As a result of this, the market for Ebola vaccine is predicted to grow significantly. However, the stringent government regulations and the lengthy drug approval procedure are some factors which are estimated to restrain the market growth in near future.
This report also provides the existing competitive scenario of some of the key players of the global Ebola vaccine market which includes company profiling of Merck & Co., Inc., Sarepta Therapeutics, Mapp Biopharmaceutical, Regeneron Pharmaceuticals, Inc., GlaxoSmithKline plc., Novavax, Inc., GeoVax, Tekmira Pharmaceuticals, NewLink Genetics Corporation and Bavarian Nordic. The profiling enfolds key information of the companies which encompasses business overview, products and services, key financials and recent news and developments. On the whole, the report depicts detailed overview of the global Ebola vaccine market that will help industry consultants, equipment manufacturers, existing players searching for expansion opportunities, new players searching possibilities and other stakeholders to align their market centric strategies according to the ongoing and expected trends in the future.